BAJAJ BROKING

Notification
No new Notification messages
Ajax Engineering IPO is Open!
Apply for the Ajax Engineering IPO through UPI in just minutes.
Q3 FY'25 Results of Top Companies!
From Reliance Industries to TCS to HDFC Bank, check out the latest quarterly results with financial highlights, key performance metrics, and more!
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Lupin Gets U.S. FDA Approval for Ipratropium Bromide Nasal Spray

Synopsis:

Lupin secured U.S. FDA approval for its Ipratropium Bromide Nasal Solution, 0.03%, a generic version of Atrovent Nasal Spray. The drug, used for rhinorrhea relief, had U.S. sales of $22 million. Lupin share price closed at ₹2,169.85, down 1.35%.


Lupin Ltd has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to manufacture and market Ipratropium Bromide Nasal Solution, 0.03% (21 mcg/spray). This drug is a generic equivalent of Atrovent Nasal Spray, 0.03%, originally developed by Boehringer Ingelheim Pharmaceuticals. The medication is prescribed for the symptomatic relief of rhinorrhea associated with allergic and non-allergic perennial rhinitis in individuals aged six years and older.

Also read: Mankind Pharma Sells Mahananda to Chalet Hotels for Rs 530 Crore

LUPIN LIMITED

Trade

2067.6-101.79 (-4.69 %)

Updated - 11 February 2025
2178.60day high
DAY HIGH
2037.05day low
DAY LOW
1125815
VOLUME (BSE)

Key Takeaways

  • FDA Approval: Lupin gains U.S. FDA clearance for Ipratropium Bromide Nasal Solution, 0.03%.

  • Market Potential: The generic equivalent of Atrovent Nasal Spray had estimated annual sales of $22 million in the U.S.

  • Production Facility: The drug will be manufactured at Lupin’s Pithampur facility in India.

  • Financial Performance: Lupin’s Q2 net profit surged 74.4% YoY to ₹852.6 crore, while revenue grew 12.6% to ₹5,672.7 crore.

Also read: Shriram Properties Signs JDA for Koyambedu Project Worth ₹350-400 Crore

Lupin’s Financial Growth and Market Impact

Lupin posted robust Q2 financial results, with a net profit of ₹852.6 crore, exceeding market expectations. The revenue reached ₹5,672.7 crore, showing a 12.6% YoY increase. EBITDA surged 46% YoY to ₹1,340.4 crore, while EBITDA margins expanded to 23.6% from 18% in the prior year.

The company’s strong operational growth reflects its strategic focus on expanding its generics portfolio. However, Lupin share price closed at ₹2,169.85 on the BSE, down by ₹29.70 or 1.35%.

Market Overview of Ipratropium Bromide Nasal Solution

Parameter

Details

Drug Name

Ipratropium Bromide Nasal Solution

Strength

0.03% (21 mcg/spray)

Equivalent to

Atrovent Nasal Spray, 0.03%

Indication

Rhinorrhea relief

Age Group

6 years and above

Manufacturing Facility

Pithampur, India

Annual U.S. Sales

$22 million

Lupin’s latest FDA approval strengthens its presence in the U.S. generics market. The company's financial resilience and new product launches indicate positive growth momentum. Investors are closely watching Lupin share price as it navigates market fluctuations.

Also read: RVNL Wins South Western Railway Project Worth ₹335.4 Crore

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9 Lacs+ Users

icon-with-text

4.1+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5100+ Cr MTF Book

icon-with-text